Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer, according to an analysis of data from the Ovarian Cancer Association Consortium presented at the 2017 Society of Gynecologic Oncology Annual Meeting.1
The efficacy of chemotherapy in women with low-grade serous ovarian cancer is not well-studied. The aim of this analysis was to determine response to chemotherapy among patients with low-grade serous ovarian cancer.
These univariable and multivariable analyses included 687 patients with a median age of 54 at diagnosis. Among the cohort, 24% had stage I, 9% stage II, 60% stage III, and 7% stage IV disease. Among patients with complete chemotherapy data, 170 received a first-line platinum-based regimen and 269 did not receive adjuvant chemotherapy.
With a median follow-up time of 4.9 years, the overall median overall survival (OS) was 8.9 years (95% CI, 7.7-10.3 years; P < .001) and the 3- and 5-year OS rates were 80% and 66%, respectively. First-line platinum-based chemotherapy did not significantly prolong survival.
RELATED: Hormonal Maintenance May Improve PFS in Low-grade Ovarian Cancer
According to the authors, these results suggest that “surgical completion to no residual disease provides a survival advantage in patients with low-grade serous ovarian carcinoma.” Adjuvant-based therapy did not, however, prolong survival in this population.
- May T, Lheureux S, Bernardini MQ, Jiang H, Tone AA. Clinical behavior of low grade serous ovarian carcinoma: an analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC). Paper presented at: 48th Annual Meeting of the Society of Gynecologic Oncology; March 12-15, 2017; National Harbor, MD.